We have studied the interaction of the Gal-GalNAc-reactive champedak lectin-C with neuraminidase-treated and untreated IgA1 from IgA nephropathy patients. The binding ability of the lectin to untreated IgA1 from IgA nephropathy patients was significantly lower as compared to the untreated IgA1 from normal controls. This differential lectin-binding capacity was abrogated when the experiment was performed on neuraminidase-treated sera. Treatment of the serum IgA1 with neuraminidase also abrogated the differential charge distribution between the α-heavy chains of IgA nephropathy patients and normal controls.

1.
Mestecky J, Hashim OH, Tomana M: Alterations in the IgA carbohydrate chains influence the cellular distribution of IgA1; in Clarkson AR, Woodroffe AJ (eds): IgA Nephropathy: Pathogenesis and Treatment. 6th International Symposium on IgA Nephropathy, Adelaide 1994. Contrib Nephrol. Basel, Karger, 1995, vol 111, pp 66–72.
2.
Andre PM, Le Pogamp P, Chevet D: Impairment of jacalin binding to serum IgA in IgA nephropathy. J Clin Lab Anal 1990;4:115–119.
3.
Mestecky J, Tomana M, Crowley-Nowick PA, Moldoveanu Z, Julian BA, Jackson S: Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy; in Bene MC, Faure M, Kessler M (eds): IgA Nephropathy: The 25th Year International Symposium, Nancy 1992. Contrib Nephrol. Basel, Karger, 1993, vol 104, pp 172–182.
4.
Hiki Y, Iwase H, Kokubo T, Horii A, Tanaka A, Nishikido J, Hotta K, Kobayashi Y: Association of asialo-galactosyl-β1,3-N-acetylgalactosamine on the hinge with a conformational instability of jacalin-reactive immunoglobulin A1 in immunoglobulin A nephropathy. J Am Soc Nephrol 1996;7:955–960.
5.
Shuib AS, Chua CT, Hashim OH: Sera of IgA nephropathy patients contain a heterogeneous population of relatively cationic alpha-heavy chains. Nephron 1998;78:290–295.
6.
Lai KN, Chui SH, Lewis WHP, Poon ASY, Lam CWK: Charge distribution of IgA-lambda in IgA nephropathy. Nephron 1994;66:38–44.
7.
Monteiro RC, Halbwachs-Mecarelli L, Roque-Barreira MC, Noel L, Berger J, Lesavre P: Charge and size of mesangial IgA in IgA nephropathy. Kidney Int 1985;28:666–671.
8.
Hashim OH, Ng CL, Gendeh GS, Nik Jaafar MI: IgA binding lectins isolated from distinct Artocarpus species demonstrate differential specificity. Mol Immunol 1991;28:393–398.
9.
Hashim OH, Gendeh GS, Nik-Jaafar MI: Comparative analyses of IgA1 binding lectins from seeds of six distinct clones of Artocarpus integer. Biochem Mol Biol Int 1993;29:69–76.
10.
Chintalacharuvu SR, Emancipator SN: The glycosylation of IgA produced by murine B cells is altered by Th2 cytokines. J Immunol 1997;159:2327–2333.
11.
Iwase H, Tanaka A, Hiki Y, Kokubo T, Ishii-Karakasa I, Kobayashi Y, Hotta K: Abundance of Galβ1,3GalNAc in O-linked oligosaccharide on hinge region of polymerized IgA1 and heat-aggregated IgA1 from normal human serum. J Biochem 1996;120:92–97.
12.
Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, Rademacher TW, Mizuochi T, Miyamoto T, Kobata A: Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985;316:452–457.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.